Name: Yang,Huijuan
Title:M.D., Ph. D, Professor

Education & Professional Experience   I was graduated from Shanghai Medical University (merged to Fudan University since 2000) in 1994, then, got the Master of Medicine degree in the same university in 1997 and Ph.D degree in the University of Hong Kong in 2004. I had my gynecological oncology training both in mainland China and HKSAR from 1997 to 2000. Since 2000, I had been an attending physician in the Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center for 7 years and associate professor for another 7 years. Now, I am a Professor in the same Department since 2014.

Clinically, I have specialized in the field of surgery and chemotherapy for women with gynecologic cancers including cervical cancer, ovarian cancer, endometrial cancer, vulvar cancer, vaginal cancer, uterine sarcoma, vulvar or vaginal melanoma, et al. My main areas of surgical expertise are open or laparoscopic radical surgery for cervical cancer, endometrial cancer and vulvar cancer, staging surgery for early-stage ovarian cancer, optimal debulking surgery for advanced ovarian cancer and secondary debulking surgery for recurrent ovarian cancer. The debulking surgery involves removing not only the cancerous ovaries but as much other tissue that the cancer may have invaded as possible (such as in the spleen, liver, diaphram, portions of the bladder, bowel, and so on), which makes the tumor much more responsive to additional treatment. Each year, around 300 patients with newly diagnosed gynecologic cancers are undergone surgery by me, half of them receive adjuvant therapy. I have also been working closely with the radiotherapists in the treatment of advanced cervical cancer and recurrent gynecologic malignancies.

In addition, I am actively involved in clinical research to help determine the best treatments for patients with gynecologic cancers, including international multicenter randomized clinical trials of new drugs, prevention and screening program of HPV infection-associated cervical, vulvar and vaginal disease in general population, strategy identification for the treatment and follow-up of cervical precursors.


I have been doing basic research on molecular markers since 1995. I have grasped various molecular biological techniques including DNA、RNA and protein extraction, immunohistochemical staining, in situ hybridization, Western blot, Southern blot, Northern blot, PCR, real-time PCR, MSP, SSCP, DNA sequencing, Methylight, CGH, Microarray, cell culture, PCR cloning, ATP assay, Clongenic assay, MTT etc. My present major research projects include T regulatory cells in cervical carcinogenesis; identification and validation of novel genetic mutations in the cervical cancers and precursors, the viral mechanisms of evasion of the immune surveillance in patients with cervical cancers and precursors, epigenetic alterations in cervical carcinogenesis , progression and metastasis. My research is supported by funding from National Natural Science Foundation of China, Ministry of Health of the People’s Republic of China, Shanghai Municipal Natural Science Foundation, shanghai municipal health bureau.

In addition to caring for patients and conducting translational research, I am actively engaged in medical education and innovative technology. I have been the sponsor for 40 clinical fellows and the mentor for 7 postgraduates. I have authored or co-authored more than 30 peer-reviewed research papers and 4 book chapters. I serve on the reviewer of 2 international journals and 3 regional journals. My goals are to provide the highest quality comprehensive care to women with gynecologic cancers and improve patient outcomes through research and education.

Publication   1.Li J, Cai Y, Ke G, Xiang L, Wang L, Yang W, Wu X, Yang H. Validation of the new FIGO staging system (2009) for vulvar cancer in the Chinese population. Gynecol Oncol. 2015 Mar 7. pii: S0090-8258(15)00675-7. doi: 10.1016/j.ygyno.2015.03.001. [Epub ahead of print]
2.Xiang L, Li J, Jiang W, Shen X, Yang W, Wu X, Yang H. Comprehensive analysis of targetable oncogenic mutations in chinese cervical cancers. Oncotarget. 2015 Mar 10;6(7):4968-75.
3.Cai Y, Sheng W, Xiang L, Wu X, Yang H*(Corresponding author). Primary extramammary Paget's disease of the vulva: The clinicopathological features and treatment outcomes in a series of 43 patients. Gynecol Oncol. 2013;129(2):412-6.
4.Aberrant DNA methylation in cervical carcinogenesis (review).Yang HJ (Corresponding author).Chin J Cancer. 2013 Jan;32(1):42-8. 
5.Xiang LB, Yang HJ*(Corresponding author), Li J, Wu XH, Zhou XY. Different amplification patterns of the human telomerase RNA gene in invasive cervical carcinomas and cervical intraepithelial neoplasia grade III and their clinical implications. Diagnostic cytopathology. 2012 Oct;40(10):849-55. 
6.Yang HJ, Liu VW, Wang Y, Tsang PC, Ngan HY. Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer. 2006 Aug 23;6:212.
7.Yang HJ, Liu VW, Tsang PC, Yip AM, Tam KF, Wong LC, Ng TY, Ngan HY. Quantification of human papillomavirus DNA in the plasma of patients with cervical cancer. Int J Gynecol Cancer. 2004 Sep-Oct;14(5):903-10.
8.Yang HJ, Liu VW, Wang Y, Chan KY, Tsang PC, Khoo US, Cheung AN, Ngan HY. Detection of hypermethylated genes in tumor and plasma of cervical cancer patients. Gynecol Oncol. 2004 May;93(2):435-40.
9.Yang HJ, Liu VW, Tsang PC, Yip AM, Ng TY, Cheung AN, Ngan HY. Comparison of human papillomavirus DNA levels in gynecological cancers: implication for cancer development.
Tumour Biol. 2003 Nov-Dec;24(6):310-6.
10.Liu VW, Yang HJ, Wang Y, Tsang PC, Cheung AN, Chiu PM, Ng TY, Wong LC, Nagley P, Ngan HY. High frequency of mitochondrial genome instability in human endometrial carcinomas. Br J Cancer. 2003 Aug 18;89(4):697-701.
11.Liu VW, Wang Y, Yang HJ, Tsang PC, Ng TY, Wong LC, Nagley P, Ngan HY. Mitochondrial DNA variant 16189T>C is associated with susceptibility to endometrial cancer. Hum Mutat. 2003 Aug;22(2):173-4.
Awards   1.Shanghai Scientific and Technological Progress Award 2007 (3rd prize), sponsored by Shanghai Municipal Government
Application of clinical technology in the treatment of advanced and recurrent ovarian cancer
2.Clinical Research Achievement Award 2007 (4th prize), sponsored by Fudan University Cancer Hospital
Differential DNA methylation profiles in gynecological cancers
3.Shanghai Scientific and Technological Progress Award 1997 (3rd prize), sponsored by Shanghai Municipal Government
Molecular alterations and their clinical implications in primary epithelial ovarian cancer
Out-patient Schedule  

Tuesday and Thursday